Scarica l'app Stockscreener
1.045
5.98%
0.059
Dopo l'orario di chiusura:
1.04
-0.005
-0.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.986
Aprire:
$0.9606
Volume 24 ore:
1.72M
Relative Volume:
0.53
Capitalizzazione di mercato:
$108.05M
Reddito:
$65,300
Utile/perdita netta:
$-84.93M
Rapporto P/E:
-0.6118
EPS:
-1.708
Flusso di cassa netto:
$-83.57M
1 W Prestazione:
-4.13%
1M Prestazione:
-9.91%
6M Prestazione:
-12.18%
1 anno Prestazione:
-58.86%
Intervallo 1D:
$0.9606
$1.06
Intervallo di 1 settimana:
$0.95
$1.18
Portata 52W:
$0.5632
$2.72
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Nome
Inovio Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 410-3134
Indirizzo
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.045 | 108.05M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-09 | Iniziato | Piper Sandler | Overweight |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-01-25 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Downgrade | Maxim Group | Buy → Hold |
| 2022-11-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Ripresa | Jefferies | Hold |
| 2021-09-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Iniziato | Jefferies | Hold |
| 2021-03-23 | Iniziato | BofA Securities | Neutral |
| 2021-02-12 | Iniziato | Oppenheimer | Outperform |
| 2020-11-17 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Aggiornamento | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-01 | Downgrade | Maxim Group | Buy → Hold |
| 2020-07-01 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Downgrade | Stifel | Buy → Hold |
| 2020-05-21 | Iniziato | The Benchmark Company | Buy |
| 2020-04-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Iniziato | ROTH Capital | Buy |
| 2018-02-15 | Reiterato | Maxim Group | Buy |
| 2017-10-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-06 | Iniziato | Citigroup | Buy |
| 2017-06-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Reiterato | Maxim Group | Buy |
| 2017-03-16 | Aggiornamento | Maxim Group | Hold → Buy |
| 2017-03-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Mostra tutto
Inovio Pharmaceuticals Inc Borsa (INO) Ultime notizie
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Price to sales ratio of Inovio Pharmaceuticals, Inc. – HAN:GBM - TradingView
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals (INO) Short Interest & Short Float | Updated Oct 2026 $INO - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer - Zacks Investment Research
Inovio Pharmaceuticals (INO) Institutional Ownership 2026 $INO - MarketBeat
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Updates Bylaws with New Exclusive-Forum Provision - The Globe and Mail
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio advances FDA review: Inovio Pharmaceuticals stock falls 3.77 percent - AD HOC NEWS
Inovio Pharmaceuticals stock fell 4.13 percent before FDA decision - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals stock approaches its October FDA test - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Debt to equity ratio of Inovio Pharmaceuticals, Inc. – HAN:GBM - TradingView
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals stock trades lower as FDA date nears - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock gains as price crosses 200-day moving average - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock trades near 52-week midpoint as analysts keep Moderate Buy view - AD HOC NEWS
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com South Africa
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com Nigeria
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms - TradingView
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms - Yahoo Finance
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com India
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP - TradingView
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP - Yahoo Finance
INOVIO at Cantor Fitzgerald healthcare conference: FDA decision nears By Investing.com - Investing.com India
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO Steps Up Investor Outreach at New York Conferences - MyChesCo
INO Stockholders Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INOVIO to Participate in Upcoming Investor Conferences - Eastern Progress
Inovio Pharmaceuticals Stock Price Forecast. Should You Buy INO? - StockInvest.us
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock gains as analysts see sharp upside - ad-hoc-news.de
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Investor talks begin Sept. 9 as INOVIO joins two conferences - Stock Titan
INOVIO to Participate in Upcoming Investor Conferences - PR Newswire
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc Azioni (INO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):